Clinical Trials Logo

Parkinson's Disease Psychosis clinical trials

View clinical trials related to Parkinson's Disease Psychosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01518309 Completed - Clinical trials for Parkinson's Disease Psychosis

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Start date: November 17, 2004
Phase: Phase 2
Study type: Interventional

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

NCT ID: NCT01174004 Completed - Clinical trials for Parkinson's Disease Psychosis

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

NCT ID: NCT00658567 Completed - Clinical trials for Parkinson's Disease Psychosis

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.

NCT ID: NCT00550238 Completed - Clinical trials for Parkinson's Disease Psychosis

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start date: July 2007
Phase: Phase 3
Study type: Interventional

To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.

NCT ID: NCT00477672 Completed - Clinical trials for Parkinson's Disease Psychosis

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start date: June 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.